XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

Acquisitions (Asset Acquisitions) (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Sep. 30, 2021 | Aug. 31, 2021 | Jul. 31, 2021 | May 31, 2021 | Mar. 31, 2021 | Jan. 31, 2021 | Jun. 30, 2020 | May 31, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  |  |  | $ 174,000,000 | $ 0 | $ 498,300,000 | $ 294,100,000
Precision Biosciences, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | $ 107,800,000 |  |  |  |  |  |  |
Merus N.V. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | 46,500,000 |  |  |  |  |  |  |
Asahi Kasei Pharma Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |
Rigel Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 125,000,000.0 |  |  |  |  |  |  |  |
MiNA Therapeutics Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |
Protomer Technologies Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 57,300,000 |  |  |  |  |  |  |  |  |  |
Kumquat Biosciences Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 55,000,000.0 |  |  |  |  |  |  |  |  |  |
Lycia Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 35,000,000.0 |  |  |  |  |  |  |  |  |  |  |
ProQR Therapeutics N.V. |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense | $ 26,700,000 |  |  |  |  |  |  |  |  |  |  |  |
Sitryx Therapeutics Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  |  | $ 52,300,000 |  |  |  |
AbCellera |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  | $ 25,000,000 | $ 25,000,000.0 |  |  |  |
Junshi Biosciences |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  | 20,000,000.0 |  |  |  |  |
Petra |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  | $ 174,800,000 |  |  |  |  |
Evox Therapeutics Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  | $ 22,000,000.0 |  |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |